DALS — DA32 Life Science Tech Acquisition Cashflow Statement
0.000.00%
Last trade - 00:00- $264.71m
- $264.40m
- 46
- 41
- 44
- 39
Annual cashflow statement for DA32 Life Science Tech Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | 10-K | 10-K |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -0.571 | 0.599 |
| Deferred Taxes | ||
| Non-Cash Items | -0.025 | -2.9 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -0.387 | 0.664 |
| Change in Prepaid Expenses | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Taxes Payable | ||
| Cash from Operating Activities | -1.97 | -2.19 |
| Other Investing Cash Flow Items | -200 | 0 |
| Change in Net Investments | ||
| Cash from Investing Activities | -400 | 0 |
| Financing Cash Flow Items | 2.82 | -0.07 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 406 | -0.14 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 1.86 | -1.17 |